<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784091</url>
  </required_header>
  <id_info>
    <org_study_id>TRS-010</org_study_id>
    <nct_id>NCT04784091</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis</brief_title>
  <acronym>Saturn-2</acronym>
  <official_title>Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarsus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tarsus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its&#xD;
      vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite&#xD;
      frequently found in human hair follicles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3 study is a randomized, controlled, multicenter, double-masked, parallel trial to&#xD;
      compare the safety and efficacy of TP-03 to vehicle control for the treatment of Demodex&#xD;
      blepharitis. The primary objective of the study is to assess the safety and efficacy of&#xD;
      TP-03, 0.25% compared to its vehicle from Day 1 to Day 43 in adult participants with mild to&#xD;
      severe Demodex blepharitis. The primary efficacy endpoint will be cure based upon&#xD;
      collarettes. Safety will be determined by assessing adverse effects related to the treatment&#xD;
      as well as evaluating any changes in visual acuity, intraocular pressure, slit lamp&#xD;
      biomicroscopy, endothelial cell density, hematology, blood chemistry, and urinalysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Active arm: TP-03, 0.25% Control arm: Vehicle of TP-03</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment assignment will be unknown to the study participant, investigators and site staff performing study assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants cured based on their collarette score</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with their Demodex mites eradicated</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants cured based on a composite of collarette score and erythema cure</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-03</intervention_name>
    <description>TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-03 Vehicle</intervention_name>
    <description>Vehicle of TP-03 ophthalmic solution, administered twice a day</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing to sign the informed consent and deemed capable of complying with the&#xD;
             requirements of the study protocol&#xD;
&#xD;
          -  Meet all of the following criteria in at least one eye: Have more than 10 lashes with&#xD;
             collarettes present on the upper lid; have at least mild erythema of the upper eyelid&#xD;
             margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or&#xD;
             more mites per lash&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have used lid hygiene products within 14 days of Screening or unwilling to forego the&#xD;
             use of lid hygiene products during the study&#xD;
&#xD;
          -  Have used a prostaglandin analogue to promote eyelash growth within 30 days of&#xD;
             Screening or any plans to initiate treatment during the study&#xD;
&#xD;
          -  Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be&#xD;
             unwilling to forego their use during the study&#xD;
&#xD;
          -  Be pregnant or lactating at the time of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Care Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yesha Raval</last_name>
    <phone>978-685-8900</phone>
    <phone_ext>9423</phone_ext>
    <email>yraval@oraclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Janeiro</last_name>
    <phone>978-685-8900</phone>
    <phone_ext>9436</phone_ext>
    <email>jjaneiro@oraclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Global Retina Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Kilgore</last_name>
      <phone>480-534-8080</phone>
      <email>lkilgore@globalretinainstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shultz Chang Vision</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Shultz</last_name>
      <phone>818-349-8300</phone>
      <email>karen.office.shultzchang@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Bay Eye Center</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94583</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Carson</last_name>
      <phone>925-830-8823</phone>
      <email>tcarson@severinmd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vision Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Agbo</last_name>
      <phone>719-559-2020</phone>
      <email>helene@vicolorado.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinnacle Research Institute</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentine Jean-Baptiste</last_name>
      <phone>954-597-6445</phone>
      <email>valentine@priclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jackson Eye, S.C.</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maggie Sawa</last_name>
      <phone>847-356-0700</phone>
      <email>maggie@myjacksoneye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michael Washburn Center for Ophthalmic Research LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gill</last_name>
      <phone>317-231-2331</phone>
      <email>jgill@whitsonvision.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kannarr Eye Care</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan Compton</last_name>
      <phone>620-235-1737</phone>
      <email>mcompton@kannarreyecare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Care Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellye Johnson</last_name>
      <phone>502-589-1500</phone>
      <email>kjohnson@eyecareinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complete Eye Care of Medina</name>
      <address>
        <city>Medina</city>
        <state>Minnesota</state>
        <zip>55340</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanaa Khimji</last_name>
      <phone>763-478-3505</phone>
      <email>skhimji@cecofmedina.com</email>
    </contact>
    <contact_backup>
      <last_name>Troy Friesen</last_name>
      <phone>763-478-3505</phone>
      <email>tfriesen@cecofmedina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Hefter</last_name>
      <phone>816-531-9100</phone>
      <email>mh@taubereye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Wiemers</last_name>
      <phone>314-966-3377</phone>
      <email>dawnwiemers@eyecare-partners.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Matossian Eye Associates</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andy Merino</last_name>
      <phone>800-708-8800</phone>
      <email>amerino@matossianeye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NC Eye Associates</name>
      <address>
        <city>Apex</city>
        <state>North Carolina</state>
        <zip>27502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Salter</last_name>
      <phone>919-363-5500</phone>
      <email>csalter@oraclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pure Ophthalmic Research</name>
      <address>
        <city>Mint Hill</city>
        <state>North Carolina</state>
        <zip>28227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Eudy</last_name>
      <phone>980-209-9437</phone>
      <email>seudy@oraclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vita Eye Clinic</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winnie Simmons</last_name>
      <phone>704-487-4099</phone>
      <email>wsimmons@oraclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Ophthalmic Associates</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Christ</last_name>
      <phone>215-885-6830</phone>
      <email>07crist957@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization / Healthy Heart Clinics of America</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexi Kenley</last_name>
      <phone>801-803-6412</phone>
      <email>lexi@alpine-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization Inc./ Country Hills Eye Center</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lexi Kenley</last_name>
      <phone>801-719-2316</phone>
      <email>lexi@alpine-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Periman Eye Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel McJunkin</last_name>
      <phone>206-347-0821</phone>
      <email>raquel@perimaneyeinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New River Vision Care</name>
      <address>
        <city>Oak Hill</city>
        <state>West Virginia</state>
        <zip>25901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Donelow</last_name>
      <phone>304-465-0269</phone>
      <email>newrivervisioncare@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Demodex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

